Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) with preferential — though not exclusive — inhibition of COX-2 over COX-1. This preferential selectivity was designed to reduce gastrointestinal toxicity compared to traditional non-selective NSAIDs, while still delivering robust anti-inflammatory and analgesic effects. It is available by prescription only (unlike ibuprofen or naproxen sodium, which are also available OTC).

Meloxicam is FDA-approved for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis in adults. It is also approved for juvenile rheumatoid arthritis (pauciarticular and polyarticular course) in children aged 2 years and older. An injectable formulation (Anjeso) was approved for moderate-to-severe pain — the first IV NSAID approved in the United States since ketorolac.

• Osteoarthritis (OA) — the most common indication
• Rheumatoid arthritis (RA) in adults
• Juvenile idiopathic arthritis (JIA) in children 2 years and older
• Moderate-to-severe pain (IV formulation, Anjeso)
• Off-label: ankylosing spondylitis, acute musculoskeletal pain, dysmenorrhea

How It Works

Meloxicam inhibits the cyclooxygenase (COX) enzyme system, reducing the conversion of arachidonic acid to prostaglandins, prostacyclin, and thromboxane. At lower concentrations, it is relatively more selective for COX-2 — the inducible form expressed primarily at sites of inflammation — compared to COX-1, the constitutively expressed form that protects the gastric mucosa and regulates platelet function.

However, it is critical to understand that meloxicam is COX-2 preferential, not COX-2 selective. At the approved strengths, it still inhibits COX-1 to a meaningful degree — it does not provide the complete gastric protection that would be expected of a fully selective COX-2 inhibitor like celecoxib. Its GI risk is somewhat lower than non-selective NSAIDs like ibuprofen at comparable anti-inflammatory amounts, but it is not eliminated. Like all NSAIDs, it carries cardiovascular and renal risks through its effects on prostaglandins in the heart and kidney.

Side Effects

Common

• Gastrointestinal: nausea, diarrhea, dyspepsia, abdominal pain — though somewhat lower incidence than non-selective NSAIDs
• Dizziness and headache
• Upper respiratory tract infections
• Peripheral edema (fluid retention)
• Hypertension or worsening of pre-existing hypertension
• Skin rash and pruritus
• Elevated liver enzymes

Serious

• Gastrointestinal ulceration, bleeding, and perforation — potentially fatal; may occur without prior warning symptoms (Boxed Warning)
• Cardiovascular thrombotic events — increased risk of heart attack and stroke, especially with longer duration and in high-risk patients (Boxed Warning)
• Acute kidney injury — particularly in volume-depleted patients, heart failure, or pre-existing renal impairment
• Severe skin reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis (rare)
• Hepatic injury — rare but serious elevations in liver enzymes; fulminant hepatitis reported rarely
• Anaphylactic reactions in aspirin-sensitive patients
• Fetal harm during pregnancy (see Warnings)

Drug Interactions

Drug / Class	Interaction	Clinical Significance
Aspirin	Meloxicam may attenuate the antiplatelet effect of aspirin. Combined use increases GI bleeding risk without proven additional cardiovascular benefit	High — avoid routine combination; take low-dose aspirin separately if cardioprotection needed
Anticoagulants (warfarin, direct oral anticoagulants)	NSAID-induced platelet dysfunction and GI mucosal vulnerability greatly increase bleeding risk when combined with anticoagulants	High — avoid combination; use acetaminophen for pain in anticoagulated patients
ACE inhibitors, ARBs, and diuretics	NSAIDs antagonize antihypertensive and diuretic effects; "triple whammy" of NSAID + ACE inhibitor/ARB + diuretic markedly increases acute kidney injury risk	High — monitor blood pressure, renal function, and electrolytes closely
Lithium	Meloxicam reduces renal lithium excretion, raising lithium levels and increasing toxicity risk	High — monitor lithium concentrations when NSAID is started or stopped
Methotrexate	NSAIDs reduce renal methotrexate clearance; increased risk of methotrexate toxicity at high doses	High — avoid in high-dose methotrexate regimens; monitor closely at low doses used in arthritis
Cyclosporine	Increased risk of cyclosporine-induced nephrotoxicity when combined with any NSAID	Moderate — monitor renal function; minimize duration
SSRIs and SNRIs	Additive impairment of platelet aggregation; combined use increases GI bleeding risk	Moderate — consider proton pump inhibitor if combination is necessary

Warnings & Contraindications

• Contraindicated: Known hypersensitivity to meloxicam or other NSAIDs; aspirin-exacerbated respiratory disease (AERD); perioperative CABG; pregnancy at 30 weeks gestation or later; severe heart failure
• GI risk reduction: Use the lowest effective amount for the shortest duration; consider concomitant PPI in high-risk patients (elderly, peptic ulcer history, corticosteroid use)
• Cardiovascular: Not a substitute for low-dose aspirin for cardiovascular protection; do not use after recent MI or stroke without careful benefit-risk assessment
• Pregnancy: Avoid from 20 weeks gestation onward due to risk of fetal renal impairment and oligohydramnios; use is contraindicated at 30+ weeks due to premature ductal closure risk
• Pediatric use: Approved for JIA in children 2 years and older; oral suspension is available for weight-based dosing in children who cannot swallow tablets
• Renal and hepatic impairment: Use with caution; severe renal impairment is a contraindication per labeling; significant hepatic impairment may require monitoring

Frequently Asked Questions

Is meloxicam better for the stomach than ibuprofen?

Meloxicam's preferential COX-2 inhibition does provide a modest gastrointestinal advantage over non-selective NSAIDs like ibuprofen in clinical trials — studies have shown lower rates of endoscopically confirmed ulcers and GI bleeding events. However, this advantage is incremental, not absolute. Meloxicam still inhibits COX-1 (and thus gastric prostaglandins) at approved amounts, meaning GI ulceration and bleeding can and do occur. High-risk patients (elderly, prior ulcer history, concurrent corticosteroid or anticoagulant use) should still use gastroprotective therapy such as a proton pump inhibitor, regardless of which NSAID is prescribed.

Can meloxicam be taken long-term for arthritis?

Many patients with osteoarthritis or rheumatoid arthritis use meloxicam on a long-term basis under medical supervision. The key principles are: use the lowest amount that adequately controls symptoms, re-evaluate the continued need periodically, monitor for signs of GI, cardiovascular, and renal complications, and consider gastroprotection with a PPI in at-risk patients. Long-term NSAID use requires ongoing prescriber oversight — it is not a benign long-term medication, particularly in older adults or those with comorbidities.

How is meloxicam different from celecoxib?

Both are designed to preferentially reduce COX-2 activity for anti-inflammatory purposes, but celecoxib is a selective COX-2 inhibitor while meloxicam is only preferential. Celecoxib provides greater relative sparing of COX-1, translating to a more favorable GI risk profile — especially relevant for patients at high GI risk. Meloxicam is generally less expensive (widely available as a generic) and is available in pediatric formulations. The cardiovascular risk profile of both is similar to other NSAIDs, particularly with longer-term use.

Does meloxicam interact with blood pressure medications?

Yes — this is an important and commonly encountered interaction. NSAIDs including meloxicam promote sodium and water retention by inhibiting prostaglandin-mediated renal vasodilation. This can blunt the effectiveness of antihypertensive medications — particularly ACE inhibitors, ARBs, diuretics, and beta-blockers — leading to blood pressure increases. Patients on antihypertensive therapy who start meloxicam should have their blood pressure monitored in the weeks following initiation. The combination of meloxicam with an ACE inhibitor or ARB plus a diuretic is particularly risky for the kidneys.

→ NSAID Side Effects Guide